Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature - 09/01/20
Abstract |
Background |
We have limited data on the treatment of calcinosis cutis associated with systemic sclerosis and dermatomyositis.
Objective |
To assess the efficacy and tolerance of available treatments for calcinosis cutis based on previously published studies.
Methods |
We performed a systematic review of studies published in Medline, Embase, and the Cochrane library during 1980-July 2018. The strength of clinical data was graded according to the modified Oxford Centre for Evidence-Based Medicine levels of evidence.
Results |
In all, 30 studies (288 patients) were included. Eleven therapeutic classes, surgery, and physical treatments were identified as potential treatment options for calcinosis cutis. On the basis of results of a small randomized controlled trial and 4 retrospective studies, low-dose warfarin should not be used for calcinosis cutis (level IB evidence). The results of several studies suggest diltiazem and bisphosphonates might be useful treatment options (level IV). Considering biologic therapies, rituximab has shown promising results in treating both dermatomyositis and systemic sclerosis, whereas tumor necrosis factor inhibitors might be useful for treating juvenile dermatomyositis (level IV). Intralesional sodium thiosulfate might be a promising alternative (level IV).
Limitations |
Few included studies had a high level of evidence.
Conclusion |
This study highlights the efficacy and tolerance profiles of available treatments for calcinosis cutis, with a focus on level of evidence.
Le texte complet de cet article est disponible en PDF.Key words : calcinosis cutis, dermatomyositis, level of evidence, systemic sclerosis
Abbreviations used : RCT, SSc, STS
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Arnaud has received honoraria from Roche-Chugaï, Grifols, LFB, Pfizer, and UCB. Dr Chizzolini has received travel support from Roche-Chugaï. Dr Traineau, Dr Aggarwal, Dr Monfort, Dr Senet, Dr Oddis, Dr Barbaud, Dr Francès, and Dr Chasset have no conflicts of interest to disclose. |
Vol 82 - N° 2
P. 317-325 - février 2020 Retour au numéro
Article précédent
- Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events
- Linda Chan, Shelley J.E. Hwang, Karen Byth, Merribel Kyaw, Matteo S. Carlino, Shaun Chou, Pablo Fernandez-Penas
- Use of antiepileptic drugs and risk of skin cancer: A nationwide case-control study
- Kasper Bruun Kristensen, Sidsel Arnspang Pedersen, Sigrun Alba Johannesdottir Schmidt, Anton Pottegård
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?